Shanghai Huaota Biopharmaceutical Co., Ltd.’s first category I biological product HB002 injection, IND number ‘CXSL1600123’, was approved by the CDE on June 20th 2017. It marks that Huaota’s first innovative biological drug has officially entered the stage of commercial clinical research.

HB002 is a new type of recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection, mainly used for the treatment of age-related macular degeneration (AMD). The drug is also known as ‘HB002.1T’, It can inhibit vascular endothelial growth as well as tumor activity. Its second indication application is intended to treat bowel cancer and gastric cancer.

the recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection (HB002.1M) will start clinical trial in July 2017.